European Journal of Dermatology最新文献_第7页

Healthcare visits, patterns of treatment, and related costs in children with controlled and uncontrolled atopic dermatitis in Sweden. 瑞典受控和未受控特应性皮炎患儿的就医情况、治疗模式和相关费用。

IF 2 4区医学

European Journal of Dermatology Pub Date : 2024-10-01 DOI: 10.1684/ejd.2024.4763

Alexandra Metsini, Linda Ryen, Scott Montgomery, Åke Svensson, Laura Von Kobyletzki

{"title":"Healthcare visits, patterns of treatment, and related costs in children with controlled and uncontrolled atopic dermatitis in Sweden.","authors":"Alexandra Metsini, Linda Ryen, Scott Montgomery, Åke Svensson, Laura Von Kobyletzki","doi":"10.1684/ejd.2024.4763","DOIUrl":"https://doi.org/10.1684/ejd.2024.4763","url":null,"abstract":"Pediatric atopic dermatitis (AD) is a common chronic disease. For assessing treatment outcomes, the concept of controlled and uncontrolled AD has been introduced. The aim of the study was to estimate healthcare resource use in terms of visits, treatments and costs in children with controlled and uncontrolled AD. The study utilised administrative data and hospital patient records. An algorithm for the identification of patients with controlled and uncontrolled AD was developed, and an assessment of content validity was performed. The study included 8,922 children, aged 0-17 years, diagnosed with AD between 2015 and 2018 in three Swedish regions, treated in primary and specialist care, at regional and university hospitals. The proposed algorithm demonstrated adequate content validity. About 13% of children had uncontrolled AD. In dermatology clinics, most patients with uncontrolled disease were 12-17 years old (39%) and 17% had moderate-to-severe AD; 2% had systemic drug treatment and 7% received UVB treatment. Uncontrolled AD was associated with treatment changes and frequent visits in specialist care over several years compared to controlled disease. The mean annual healthcare cost of a child with AD aged 0-17 years in Sweden was estimated at €4,479.5. There was a statistically significant cost difference (around €4000 annually) between patients with uncontrolled AD and those with controlled disease. AD was associated with high healthcare utilization, especially for children with uncontrolled disease. A high proportion of children with AD might be undertreated, and risk groups, such as adolescents with uncontrolled AD, should be treated more effectively.","PeriodicalId":11968,"journal":{"name":"European Journal of Dermatology","volume":"34 5","pages":"509-516"},"PeriodicalIF":2.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics of post-irradiation morphea in non-breast cancer patients. 非乳腺癌患者放疗后病变的特征。

IF 2 4区医学

European Journal of Dermatology Pub Date : 2024-10-01 DOI: 10.1684/ejd.2024.4762

Haruna Kimura, Natsumi Hama, Yuki Akihiko, Koichiro Nozaki, Toshiaki Kikuchi, Hiroe Sato, Motoki Kaidu, Riichiro Abe

引用次数: 0

Effectiveness and safety of tralokinumab treatment for moderate-to-severe atopic dermatitis in real-world clinical practice in Japan. 在日本的实际临床实践中，曲妥珠单抗治疗中重度特应性皮炎的有效性和安全性。

IF 2 4区医学

European Journal of Dermatology Pub Date : 2024-10-01 DOI: 10.1684/ejd.2024.4750

Teppei Hagino, Marina Onda, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

{"title":"Effectiveness and safety of tralokinumab treatment for moderate-to-severe atopic dermatitis in real-world clinical practice in Japan.","authors":"Teppei Hagino, Marina Onda, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda","doi":"10.1684/ejd.2024.4750","DOIUrl":"https://doi.org/10.1684/ejd.2024.4750","url":null,"abstract":"Tralokinumab is a human monoclonal anti-interleukin-13 antibody approved as systemic treatment for atopic dermatitis (AD). We aimed to evaluate effectiveness and safety of tralokinumab for AD in real-world clinical practice. We analysed Japanese patients with AD from October 2023 to March 2024. All patients were subcutaneously injected with tralokinumab, 300 mg every two weeks, after an initial injection of 600 mg and twice-daily topical corticosteroids of moderate to strongest class until week 12. In this study, 103 patients were analysed. At week 4 and 12, 54.7 % and 83.0 % achieved eczema area and severity index (EASI) 50, 22.7 % and 38.3 % achieved EASI 75, 90 8.0 % and 23.4 % achieved EASI, 32.0 % and 55.3 % achieved EASI ≤7, and 1.3 % and 14.0 % achieved Investigator's Global Assessment 0/1, respectively. At week 4 and 12, 52.9 % and 51.2 % achieved Peak Pruritus-Numerical Rating Scale (PP-NRS) 4, 16.5 % and 15.6 % achieved PP-NRS ≤1, and 57.9 % and 75.0 % achieved Atopic Dermatitis Control Tool 7, respectively. Serum levels of immunoglobulin E, thymus and activation-regulated chemokine, and lactate dehydrogenase significantly decreased at week 12 compared to baseline. Treatment-emergent adverse events occurred in 14.8 % of patients, which were mild and manageable. Notably, conjunctivitis occurred in 2.9 % of patients but was mild and resolved spontaneously. Tralokinumab for patients with AD was well-tolerated and provided favourable therapeutic effects in real-world clinical practice.","PeriodicalId":11968,"journal":{"name":"European Journal of Dermatology","volume":"34 5","pages":"525-532"},"PeriodicalIF":2.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spontaneous regression of methotrexate-associated lymphoproliferative disease associated with polyclonal antibody production by plasma cells. 与浆细胞产生多克隆抗体有关的甲氨蝶呤相关淋巴组织增生性疾病的自然消退。

IF 2 4区医学

European Journal of Dermatology Pub Date : 2024-10-01 DOI: 10.1684/ejd.2024.4771

Taisuke Uchida, Takuya Inoue, Kazunari Sugita

引用次数: 0

Pemphigus vulgaris with concurrent herpes simplex virus infection: a debatable dermatological dilemma. 丘疹性荨麻疹并发单纯疱疹病毒感染：一个值得商榷的皮肤病难题。

IF 2 4区医学

European Journal of Dermatology Pub Date : 2024-10-01 DOI: 10.1684/ejd.2024.4778

Thanaporn Puaratanaarunkon, Pravit Asawanonda, Chanat Kumtornrut

引用次数: 0

Coexistence of early localized and late disseminated cutaneous borreliosis in the same patient. 同一患者同时患有早期局部性和晚期播散性皮肤包虫病。

IF 2 4区医学

European Journal of Dermatology Pub Date : 2024-10-01 DOI: 10.1684/ejd.2024.4765

Rémy Hamdan, Anne-Laure Baldassini, Anh-Thu Phan Thi, Cédric Lenormand, Véronique Jacomo, Olivier Harou, Gilles Mauduit, Annabelle Paleau, Catherine Falchero

引用次数: 0

sQUIZ your knowledge! Not your usual hand foot syndrome: peculiar taxane toxicity worth remembering. 唤醒您的知识！非同寻常的手足综合症：值得记住的特殊类固醇毒性。

IF 2 4区医学

European Journal of Dermatology Pub Date : 2024-10-01 DOI: 10.1684/ejd.2024.4781

Joana Xara, Duarte Flor, Mónica Mariano, Inês Coutinho

引用次数: 0

sQUIZ your knowledge! A painful plaque on the heel of a young female. 测验您的知识！年轻女性脚后跟上的疼痛斑块。

IF 2 4区医学

European Journal of Dermatology Pub Date : 2024-10-01 DOI: 10.1684/ejd.2024.4776

Yoshitsugu Sunaga, Takayuki Suyama

引用次数: 0

Reflectance confocal microscopy for the diagnosis of facial cutaneous lupus erythematosus and tinea incognito in children: a retrospective study. 反射共聚焦显微镜用于诊断儿童面部皮肤红斑狼疮和癣菌：一项回顾性研究。

IF 2 4区医学

European Journal of Dermatology Pub Date : 2024-10-01 DOI: 10.1684/ejd.2024.4766

Lixin Chen, Ying Wang, Min Ren, Xiaofang Ping, Qinfeng Li

引用次数: 0

VAV1 regulates cell growth in cutaneous T-cell lymphoma via the BAMBI/BMF signalling pathway. VAV1 通过 BAMBI/BMF 信号通路调节皮肤 T 细胞淋巴瘤的细胞生长。

IF 2 4区医学

European Journal of Dermatology Pub Date : 2024-10-01 DOI: 10.1684/ejd.2024.4752

Yimeng Wang, Tingting Li, Guanyu Wang, Chunlei Zhang

{"title":"VAV1 regulates cell growth in cutaneous T-cell lymphoma via the BAMBI/BMF signalling pathway.","authors":"Yimeng Wang, Tingting Li, Guanyu Wang, Chunlei Zhang","doi":"10.1684/ejd.2024.4752","DOIUrl":"https://doi.org/10.1684/ejd.2024.4752","url":null,"abstract":"Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of tumours originating from the cutaneous infiltration of clonal malignant T cells. VAV1 is a hematopoietic signal transducer and an oncogene in various cancers, however, the relevance of aberrant VAV1 expression in CTCL pathogenesis remains unclear. This study aimed to evaluate the expression pattern and underlying pathogenic mechanisms of VAV1 in CTCLs. The expression of VAV1 in CTCL tumour tissues and benign inflammatory dermatoses skin samples were examined by immunohistochemistry. CTCL cells were also transfected with lentiviral-based VAV1 gene knockdown vectors, and the effects of VAV1 knockdown on cell proliferation and apoptosis in CTCL cells was determined by MTS assay and flow cytometry. Transcriptomic sequencing was performed to detect the direct downstream targets of VAV1 silencing. RT-qPCR and western blot analysis were used to verify the transcriptomic analysis results. High expression of VAV1 was observed in CTCL tissues (n = 25) compared with benign inflammatory dermatoses (n = 23) using immunohistochemistry. VAV1 knockdown in two CTCL cell lines decreased cell proliferation and increased the percentage of apoptotic cells. Moreover, messenger RNA and protein expression of Bcl-2-modifying factor was increased, whereas that of bone morphogenetic proteins and activin membrane-bound inhibitor was downregulated in VAV1-silenced CTCL cells. VAV1 silencing induces apoptosis and inhibits cell growth, which is associated with upregulation of Bcl-2 modifying factor and downregulation of bone morphogenetic proteins and activin membrane-bound inhibitor. Therefore, VAV1 may be a potential tumour marker and therapeutic target for CTCLs.","PeriodicalId":11968,"journal":{"name":"European Journal of Dermatology","volume":"34 5","pages":"480-489"},"PeriodicalIF":2.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0